USPTO 2015–2025 USPTO PatentsView Foreign Corporation

GLAXOSMITHKLINE BIOLOGICALS SA

USPTO PatentsView assignee record — 436 granted patents across 31 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

436
Total patents granted
31
CPC technology areas
17.7
Avg claims per patent
-10%
5-year filing velocity

Portfolio overview

GLAXOSMITHKLINE BIOLOGICALS SA has been granted 436 US utility patents between 2015 and 2025, placing GLAXOSMITHKLINE BIOLOGICALS SA at rank #1,007 across all assignees tracked by PlainPatent. This portfolio spans 31 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.7 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, GLAXOSMITHKLINE BIOLOGICALS SA is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 58.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 206 grants, compared with 230 in the 2015–2019 window — a -10% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. GLAXOSMITHKLINE BIOLOGICALS SA's 17.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 31 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark GLAXOSMITHKLINE BIOLOGICALS SA against peers pursuing similar technology classes.

How does GLAXOSMITHKLINE compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows GLAXOSMITHKLINE holds 436 patents — placing it at rank #1,007 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

102030405060 20152016201720182019202020212022202320242025 13
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
GLAXOSMITHKLINE BIOLOGICALS SA patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 35 8.0%
2016 57 13.1%
2017 54 12.4%
2018 37 8.5%
2019 47 10.8%
2020 38 8.7%
2021 32 7.3%
2022 34 7.8%
2023 52 11.9%
2024 37 8.5%
2025 13 3.0%

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#1,007

Across all tracked assignees

Innovation Score

58.3 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does GLAXOSMITHKLINE BIOLOGICALS SA hold?
GLAXOSMITHKLINE BIOLOGICALS SA holds 436 US granted patents filed between 2015 and 2025, spanning 31 technology areas.
What is GLAXOSMITHKLINE BIOLOGICALS SA's Innovation Score?
GLAXOSMITHKLINE BIOLOGICALS SA has an Innovation Score of 58.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does GLAXOSMITHKLINE BIOLOGICALS SA focus on?
GLAXOSMITHKLINE BIOLOGICALS SA's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 409 patents. The company has filed patents in 31 CPC subclasses total.
Is GLAXOSMITHKLINE BIOLOGICALS SA's patent filing rate increasing or decreasing?
GLAXOSMITHKLINE BIOLOGICALS SA's recent filing velocity is -10% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for GLAXOSMITHKLINE BIOLOGICALS SA's patents?
GLAXOSMITHKLINE BIOLOGICALS SA's patents average 17.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the GLAXOSMITHKLINE BIOLOGICALS SA patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope